PNPLA3 and fatty liver disease: <i>PNPLA3</i> may influence triglyceride hydrolysis via adipose triglyceride lipase, contributing to fatty liver disease and elevating CVD risk.<h4>Conclusion</h4>SNPs in <i>PNPLA3</i> and <i>APOE</i> may contribute to increased CVD risk among PLWH receiving ART.